131.87
+0(+0.00%)
Currency In USD
Address
430 East 29th Street
New York City, NY 10016
United States of America
Phone
646 440 9333
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
860
First IPO Date
January 07, 2014
| Name | Title | Pay | Year Born |
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & Chief Executive Officer | 3.31M | 1953 |
| Mr. Juan Fernando Sanchez M.D. | Vice President of Corporate Communications & Investor Relations | 296,753 | 1971 |
| Dr. Robert E. Davis Ph.D. | Senior Vice President & Chief Scientific Officer | 646,124 | 1951 |
| Mr. Sanjeev Narula | Executive Vice President, Chief Financial Officer & Treasurer | 665,479 | 1962 |
| Dr. Suresh K. Durgam M.D. | Executive Vice President & Chief Medical Officer | 1.21M | 1970 |
| Mr. Mark Neumann | EVice President & Chief Commercial Officer | 1.26M | 1964 |
| Mr. Michael I. Halstead J.D. | President | 1.36M | 1973 |
| Dr. Michael Olchaskey Pharm.D. | Senior Vice President & Head of Regulatory Affairs | 0 | N/A |
| John P. Condon | Senior Vice President, General Counsel & Secretary | 0 | N/A |
| Ms. Karen Patruno Sheehy Esq. | Senior Vice President & Chief Compliance Officer | 0 | 1962 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.